(Bexmarilimab)Biosimilar Reference Antibody-GS40083 新品

货号：GS40083

Bexmarilimab is an investigational, first-in-class bispecific antibody designed as a macrophage-reprogramming immunotherapy. It simultaneously targets two receptors on tumor-associated macrophages (TAMs): Clever-1 (also known as Stabilin-1 or STAB1) and an undisclosed second immune cell receptor (widely reported to be CD40). Its dual mechanism aims to repolarize immunosuppressive “M2-like” TAMs into pro-inflammatory, anti-tumor “M1-like” macrophages and to enhance antigen presentation. It is currently in clinical development (Phase I/II) for the treatment of advanced solid tumors, particularly those with a “cold” tumor microenvironment, such as certain liver and biliary tract cancers.